Brief: Evotec Announces Nomination Of First Preclinical Development Candidate In Dermatology Collaboration With Almirall
May 4 (Reuters) - EVOTEC SE EVTG.DE: ANNOUNCES NOMINATION OF FIRST PRECLINICAL DEVELOPMENT CANDIDATE IN DERMATOLOGY COLLABORATION WITH ALMIRALL PROGRAM IS AIMED AT DEVELOPING NOVEL TREATMENTS FOR IMMUNE‑MEDIATED INFLAMMATORY SKIN DISEASES WITH HIGH UNMET MEDICAL NEED Source text: ID:nEQTsfGfa Further company coverage: EVTG.DE (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Evotec SE
See all newsEvotec up 7% in early trade after 9-month revenue, earnings beat
Brief: Evotec Says Preliminary Nine-Month 2026 Results Above Market Expectations
Brief: Evotec Initiates Phase 1 Trial For Jst-018 Antibodies Targeting Orthopoxviruses
Brief: EVOTEC Q2 Group Revenues €143.50 Mln
Brief: Evotec And Odyssey Therapeutics Enter AI-Enabled R&D Collaboration In Autoimmune And Inflammatory Diseases